The role of wild type RAS isoforms in cancer

Area of Science:

• Oncogenic signaling pathways
• Cancer genetics and molecular biology

Background:

• RAS proteins (HRAS, KRAS, NRAS) are key drivers in approximately 30% of human cancers.
• The roles of wild type RAS proteins in cancer are complex and context-dependent, influenced by specific mutations, isoforms (e.g., KRAS4A, KRAS4B), and signaling networks.
• Genetic aberrations in cancers, with or without RAS mutations, add further complexity.

Purpose of the Study:

• To explore the current understanding of the multifaceted roles of wild type RAS proteins in human cancers.
• To elucidate how wild type RAS proteins function as either tumor suppressors or promoters based on the presence and type of RAS mutations.

Main Methods:

• Review of extensive mouse model carcinogenesis studies.
• Examination of patient tumor data.
• Analysis of genetic aberrations and signaling pathway interactions.

Main Results:

• In RAS-mutant cancers, wild type RAS proteins may act as tumor suppressors if the mutation is in the same isoform (e.g., wild type KRAS in KRAS-mutant cancers).
• Wild type RAS proteins appear to promote tumors when the RAS mutation is in a different isoform.
• In non-RAS mutant cancers, wild type RAS can mediate oncogenic signaling through activated receptor tyrosine kinases or loss of negative regulators.

Conclusions:

• Wild type RAS proteins exhibit dual roles in oncogenesis, acting as tumor suppressors or promoters depending on the specific mutational context.
• The isoform of the RAS mutation is a critical determinant of wild type RAS function.
• Further research is needed to fully elucidate the intricate mechanisms governing wild type RAS activity in various cancer types.